Table 3 Comparison of intervention for AMS between small/middle-sized hospitals and large hospitals
Total n = 39 | Small/middle-sized hospitals (≤ 500 beds) n = 21 | Large hospitals (≥ 501 beds) n = 18 | OR | 95% CI | p value | ||||
|---|---|---|---|---|---|---|---|---|---|
Intervention within 7 days | |||||||||
Overall | 17 | (43.6) | 13 | (61.9) | 4 | (22.2) | 5.7 | 1.4–23.5 | 0.023 |
Carbapenem | 16 | (41.0) | 12 | (57.1) | 4 | (22.2) | 4.7 | 1.1–19.1 | 0.049 |
3rd generation cephalosporine | 1 | (2.6) | 1 | (4.8) | 0 | (0) | |||
4th generation cephalosporine | 7 | (17.9) | 6 | (28.6) | 1 | (5.6) | 6.8 | 0.7–63.1 | 0.098 |
Piperacillin/tazobactam | 12 | (30.8) | 10 | (47.6) | 2 | (11.1) | 7.3 | 1.3–39.9 | 0.018 |
Intravenous quinolone | 13 | (30.8) | 11 | (52.4) | 2 | (11.1) | 8.8 | 1.6–48.2 | 0.008 |
Intervention within 28 days | |||||||||
Overall | 34 | (87.2) | 20 | (95.2) | 14 | (77.8) | 5.7 | 0.6–56.7 | 0.16 |
Carbapenem | 34 | (87.2) | 20 | (95.2) | 14 | (77.8) | 5.7 | 0.6–56.7 | 0.16 |
3rd generation cephalosporine | 11 | (28.2) | 7 | (33.3) | 4 | (22.2) | 1.8 | 0.4–7.4 | 0.50 |
4th generation cephalosporine | 20 | (51.3) | 13 | (61.9) | 7 | (38.9) | 2.6 | 0.7–9.3 | 0.21 |
Piperacillin/tazobactam | 23 | (59.0) | 14 | (66.7) | 9 | (50.0) | 2.0 | 0.6–7.3 | 0.34 |
Intravenous quinolone | 22 | (56.4) | 14 | (66.7) | 8 | (44.4) | 2.5 | 0.7–9.2 | 0.21 |